Containing Discrete Coated Particles Pellets, Granules, Or Beads Patents (Class 424/458)
-
Publication number: 20070218126Abstract: Compositions and methods for reducing inflammation and pain associated with acidosis. One embodiment of the composition comprises a plurality of carrier particles, wherein the plurality of carrier particles hold a plurality of alkaline compounds, and wherein the alkaline compounds can be delivered to, and absorbed across, lipid membranes into the blood stream in small quantities over an extended period of time.Type: ApplicationFiled: March 16, 2007Publication date: September 20, 2007Applicant: Tamer Laboratories, Inc.Inventors: Macit Gurol, Robert Burns, Candace McNaughton
-
Publication number: 20070202162Abstract: The present invention relates to extended release pharmaceutical compositions comprising a beta-blocker drug or a pharmaceutically acceptable salt thereof, wherein said composition comprises at least two extended release portions, each portion having an in vitro dissolution profile that is different from another portion.Type: ApplicationFiled: February 23, 2007Publication date: August 30, 2007Inventors: Anand Sankarnarayanan, Subhash Pandurang Gore, Ravinder Kodipyaka, Indu Bhushan, Mailatur Sivaraman Mohan
-
Patent number: 7217431Abstract: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.Type: GrantFiled: July 5, 2002Date of Patent: May 15, 2007Assignee: LifeCycle Pharma A/SInventors: Per Holm, Anders Buur, Michiel Onne Elema, Birgitte Møllgaard, Jannie Egeskov Holm, Kirsten Schultz
-
Patent number: 7211275Abstract: Composite materials comprising a water-soluble compound adsorbed onto a basic inorganic material and a bio-degradable polymer which yields acidic degradation products, methods of producing same, and methods of use thereof are described, wherein the composite materials are designed so as to provide controlled release of the water soluble molecule.Type: GrantFiled: January 13, 2005Date of Patent: May 1, 2007Assignee: Massachusetts Institute of TechnologyInventors: Jackie Y. Ying, Tseh-Hwan Yong
-
Patent number: 7208460Abstract: The present invention relates to an improved controlled delivery system that can be incorporated in soap bars to enhance deposition of active ingredients and sensory markers onto skin. The carrier system also provides controlled release or prolonged release of these actives from the skin over an extended period of time. The controlled delivery system of the present invention comprises substantially free-flowing, powder formed of solid hydrophobic, positively charged, nanospheres of encapsulated active ingredients, that are encapsulated in moisture sensitive microspheres. The high cationic charge density of the nanosphere improves deposition of active ingredients onto skin.Type: GrantFiled: September 24, 2004Date of Patent: April 24, 2007Assignee: Salvona IP, LLCInventors: Adi Shefer, Samuel Shefer
-
Patent number: 7195769Abstract: A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.Type: GrantFiled: April 10, 2001Date of Patent: March 27, 2007Assignee: Panacea Biotec LimitedInventors: Amarjit Singh, Rajesh Jain
-
Patent number: 7186418Abstract: The invention provides compositions comprising an RAR antagonist for promoting chondrogenesis and methods employing such compositions for treating cartilage and associated bone abnormalities resulting from injury or disease and for ex vivo tissue engineering.Type: GrantFiled: November 19, 1999Date of Patent: March 6, 2007Assignee: University of Western OntarioInventors: Tully Michael Underhill, Andrea Dawn Weston
-
Patent number: 7157103Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.Type: GrantFiled: August 6, 2002Date of Patent: January 2, 2007Assignee: Euro-Celtique S.A.Inventor: Richard Sackler
-
Patent number: 7153840Abstract: This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.Type: GrantFiled: May 23, 2003Date of Patent: December 26, 2006Assignee: Sicor, Inc.Inventors: Dorla Mirejovsky, Peter Lindsay Macdonald
-
Patent number: 7148207Abstract: This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.Type: GrantFiled: December 20, 2002Date of Patent: December 12, 2006Assignee: Schering AktiengesellschaftInventors: Wolfgang Heil, Ulf Tistam, Ralph Lipp, Johannes-Wilhelm Tack
-
Patent number: 7144587Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to impart a bitter taste to an abuser upon administration of the dosage form after tampering.Type: GrantFiled: August 6, 2002Date of Patent: December 5, 2006Assignee: Euro-Celtique S.A.Inventors: Benjamin Oshlack, Robert Colucci, Curtis Wright, Christopher Breder
-
Patent number: 7141250Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter taste to an abuser upon administration of said dosage form after tampering.Type: GrantFiled: August 6, 2002Date of Patent: November 28, 2006Assignee: Euro-Celtique S.A.Inventors: Benjamin Oshlack, Robert Colucci, Curtis Wright, Christopher Breder
-
Patent number: 7122207Abstract: A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, and partially pregelatinized corn starch. A high drug load pharmaceutical composition, comprising the beadlet, with an enteric coating disposed thereon, is also provided.Type: GrantFiled: May 3, 2001Date of Patent: October 17, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Gary J Wiley
-
Patent number: 7108866Abstract: A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.Type: GrantFiled: May 8, 2000Date of Patent: September 19, 2006Assignee: Biovall Laboratories International SRLInventors: Kenneth Stephen Albert, Paul José Maes
-
Patent number: 7087249Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.Type: GrantFiled: April 23, 2002Date of Patent: August 8, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
-
Patent number: 7083808Abstract: The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release methylphenidate formulations, and the duration of effect falls rapidly at the end of the dosing interval so as not to affect the appetite of the patient at dinner nor the patient's sleep thereafter.Type: GrantFiled: December 19, 2003Date of Patent: August 1, 2006Assignee: Euro-Celtique S.A.Inventors: Paul D. Goldenheim, Richard S. Sackler, Thinnayam N. Krishnamurthy, Andrew Darke, Benjamin Oshlaci
-
Patent number: 7070803Abstract: Novel controlled release pharmaceutical compositions for oral use containing midodrine and/or its active metabolite desglymidodrine. The novel compositions are designed to release midodrine and/or desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active metabolite desglymidodrine is obtained followed by a prolonged and relatively constant plasma concentration of desglymidodrine. The novel compositions may be designed for administration once or twice daily, i.e. a therapeutically effective concentration of desglymidodrine is maintained for a period of at least 10-16 hours followed by a wash out period of about 8-12 hours in order to avoid the well-known midodrine related side effect with respect to supine hypertension. The therapeutically effective concentration of desglymidodrine is regarded as a plasma concentration of desglymidodrine of at least about 3 ng/ml.Type: GrantFiled: March 29, 2001Date of Patent: July 4, 2006Assignee: Nycomed Austria GmbHInventors: Annette Skinhøj, Peder Mohr Olsen, Poul Bertelsen
-
Patent number: 7060293Abstract: An oral dosage form of morphine is formulated by powder-layering an homogeneous mixture of morphine sulfate and hydrous lactose impalpable onto inert beads to obtain a multiparticulate product. A plurality of the powder-layered beads may be administered either in immediate release form or in an extended release form by coating with a hydrophobic material. In addition, multi-particulate oral dosage forms containing therapeutically effective agents containing a plurality of pharmaceutically acceptable inert beads powder-layered with homogeneous mixture of a therapeutically effective agent and hydrous lactose impalpable are also disclosed. A method of preparing the dosage forms as well as a method preparing spheroids containing the homogeneous mixture of therapeutically effective agent and hydrous lactose impalpable are also disclosed.Type: GrantFiled: June 20, 2000Date of Patent: June 13, 2006Assignee: Purdue PharmaInventors: Benjamin Oshlack, Frank Pedi, Jr.
-
Patent number: 7060263Abstract: An improved soft gelatin formulation and process methodology that increases single Coenzyme Q10 molecules presented to the absorption channels of the small intestines by providing medium chain triglycerides, Vitamin E and natural beta carotene to Coenzyme Q10 in a soft gel capsule to increase the absorption thereof.Type: GrantFiled: August 14, 2003Date of Patent: June 13, 2006Inventors: Ronald G. Udell, Siva P. Hari
-
Patent number: 7048945Abstract: A pharmaceutical dosage form such as a capsule capable of delivering therapeutic agents into the body in a time-controlled or position-controlled pulsatile release fashion, is composed of a multitude of multicoated particulates (beads, pellets, granules, etc.) made of one or more populations of beads. Each of these beads except an immediate release bead has at least two coated membrane barriers. One of the membrane barriers is composed of an enteric polymer while the second membrane barrier is composed of a mixture of water insoluble polymer and an enteric polymer. The composition and the thickness of the polymeric membrane barriers determine the lag time and duration of drug release from each of the bead populations. Optionally, an organic acid containing intermediate membrane may be applied for further modifying the lag time and/or the duration of drug release.Type: GrantFiled: September 30, 2003Date of Patent: May 23, 2006Assignee: Eurand Pharamaceuticals, Ltd.Inventors: Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh, Der Yang Lee
-
Patent number: 7030162Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.Type: GrantFiled: September 26, 2002Date of Patent: April 18, 2006Assignee: POZEN Inc.Inventors: John R. Plachetka, Zakauddin T. Chowhan
-
Patent number: 7022350Abstract: A dietary supplement for treating or preventing prostate disease and/or vascular disease including saw palmetto, d-alpha tocopherol, d-gamma tocopherol, d-delta tocopherol, d-beta tocopherol, selenium, lycopene, zinc, folic acid, vitamin B12, and vitamin B6, each in a therapeutically effective amount.Type: GrantFiled: April 27, 2004Date of Patent: April 4, 2006Assignee: Proethic Pharmaceuticals, Inc.Inventors: Bryce M. Harvey, Philip M. Knight
-
Patent number: 7019106Abstract: A process for producing a lactic acid polymer of 15,000 to 50,000 in weight-average molecular weight, the content of polymeric materials having not more than about 5,000 in weight-average molecular weight therein being not more than about 5% by weight, characterized by hydrolyzing a high molecular weight lactic acid polymer, placing the resultant solution comprising the hydrolyzed product under a condition capable of precipitating the objective lactic acid polymer, separating the precipitated lactic acid polymer and collecting them. The lactic acid polymer is useful as a matrix for sustained-release preparations. The sustained-release microcapsule preparation encapsulating a physiologically active substance can fully prevent the initial excessive release of the physiologically active substance from the microcapsules and keep a stable release rate over a long period of time.Type: GrantFiled: August 6, 2001Date of Patent: March 28, 2006Assignees: Wako Pure Chemical Industries, Ltd., Takeda Pharmaceutical Company LimitedInventors: Kohei Yamamoto, Tsutomu Tani, Takashi Aoki, Yoshio Hata
-
Patent number: 7014859Abstract: A nematode collected from Diaprepes abbreviatus was identified and described as a new species, Steinernema diaprepesi n. sp. The new species can be distinguished from other species of the genus by the following characteristics: Males: Spicule averaging 79 (71–90) Fm; the ratio D % (distance from the anterior end/esophagus length×100) about 80; the ratio SW (spicule length/anal body width) about 1.8. Females: Vulva with short, double flapped epiptygma; tail terminus usually with 5 mucrons. Infective juveniles: Body averaging 1002 (880–1133) Fm, EP (distance from anterior end to excretory pore)=74 (66–83) Fm; tail length=83 (65–91) Fm, and E % (EP/tail length)=89.6 78–114). Lateral field pattern variable, the formula for the arrangement of ridges from head to tail is: 2, 6, 7, 8, 4, 2. The portion with 8 ridges is the longest. This new species can be differentiated from the 3 closest species, S. feltiae, S. glaseri, and S. oregonense by characteristics of their sequences.Type: GrantFiled: July 18, 2002Date of Patent: March 21, 2006Assignee: University of Florida Research Foundation, Inc.Inventors: Larry W. Duncan, Khuong B. Nguyen
-
Patent number: 7011847Abstract: Pharmaceutical compositions and methods of using the composition are provided. The pharmaceutical composition comprises an inert core surrounded by an active coating containing one or more bisphosphonic acids or salts thereof, a seal coating surrounding the active coating and an enteric coating surrounding the seal coating. Alendronic acid and alendronate sodium trihydrate are the preferred active ingredients. The composition may be provided in the form of pellets in a capsule or Peltabs. The invention further provides methods for the treatment of disorders caused by the abnormal dissolution or deposition of calcium salts using the inventive compositions.Type: GrantFiled: October 16, 2003Date of Patent: March 14, 2006Assignee: U & I Pharmaceuticals Ltd.Inventors: Amar Lulla, Geena Malhotra
-
Patent number: 7008640Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.Type: GrantFiled: July 16, 2001Date of Patent: March 7, 2006Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Hiromu Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada
-
Patent number: 6994873Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.Type: GrantFiled: February 4, 2002Date of Patent: February 7, 2006Assignee: Valpharma S.A.Inventors: Roberto Valducci, Tiziano Alighieri, Serozh Avanessian
-
Patent number: 6991807Abstract: Disclosed are antibiotic products for delivering at least two different antibiotics, wherein the products are comprised of at least three or four dosage forms with different release profiles and the at least two different antibiotics comprise at least one protein synthesis inhibiting antibiotic and at least one non-protein synthesis inhibiting antibiotic.Type: GrantFiled: May 19, 2003Date of Patent: January 31, 2006Assignee: Advancis Pharmaceutical, Corp.Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Patent number: 6989159Abstract: Once daily pharmaceutical compositions containing lithium carbonate in the form of coated granules.Type: GrantFiled: August 6, 2001Date of Patent: January 24, 2006Assignee: JDS Pharmaceuticals, LLCInventor: Giulio Tarro
-
Patent number: 6979468Abstract: A method and composition for the treatment of acne vulgaris, acne rosacea, and other inflammatory skin conditions comprises the oral administration of a composition comprising a dose of nicotinamide delivered at levels substantially in excess of normal dietary levels, the nicotinamide being delivered in combination with zinc. The composition may also include quantities of copper and folic acid. In a most preferred embodiment, the nicotinamide and copper each are present in immediate release formats, while the zinc is present in a sustained release format.Type: GrantFiled: December 6, 2002Date of Patent: December 27, 2005Assignee: Sirius LaboratoriesInventor: Frank Pollard
-
Patent number: 6962717Abstract: A pharmaceutical composition for slow release of active ingredient in the gastrointestinal tract, comprising a plurality of active ingredient-containing particles coated with a material insoluble in gastric and intestinal juices, where the particles have as core a homogeneous mixture comprising an active pharmaceutical ingredient and a polymer insoluble in gastric and intestinal juices, with an average internal pore diameter not exceeding 35 ?m, makes efficient and pH-independent delaying of release possible even with comparatively small amounts of polymer. It is additionally distinguished by a long shelf life and is particularly suitable also for nonspherical particles.Type: GrantFiled: January 29, 1999Date of Patent: November 8, 2005Assignee: Disphar International B.V.Inventors: Gerald Huber, Peter Gruber
-
Patent number: 6958161Abstract: A modified release preparation having one or more coated core elements, each core element including an active ingredient and having a modified release coating, wherein a stabilising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile.Type: GrantFiled: April 12, 2002Date of Patent: October 25, 2005Assignee: F H Faulding & Co LimitedInventors: David Hayes, Angelo LoPore, Stefan Lukas, Eugene Quinn
-
Patent number: 6955821Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions has at least one additional drug ingredient.Type: GrantFiled: April 15, 2002Date of Patent: October 18, 2005Assignee: Adams Laboratories, Inc.Inventors: Robert D. Davis, Ralph W. Blume, Donald Jeffrey Keyser
-
Patent number: 6933380Abstract: The present invention provides low-residual-solvent containing excipients with residual solvent less than <3000 ppm. Most of the excipients are required to first be modified to become more water absorbing such as by attaching a water absorbing radical, e.g., (—CH2COONa) to the carbinol groups (—CH2OH) of the excipients to form a —CH2—O—CH2COONa linkage. The linkage of the water-absorbing groups to e excipients improves the water absorbing property of the excipients, which facilitates the replacing residual solvent with water. The residual solvent can be extracted from the excipient by way of mixing with a solvent/water solution containing (1) about 75-95% (v/v) isopropanol and about 5-25% water (v/v); (2) about 65-95% acetone and about 5-35% water; and (3) about 60-85% methanol and about 15-40% water.Type: GrantFiled: November 26, 2001Date of Patent: August 23, 2005Assignee: Yung-Zip Chemical Ind. Co., Ltd.Inventors: Yun-Peng Huang, Fangchan Lee, Jer-Yen Shaw
-
Patent number: 6911217Abstract: A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.Type: GrantFiled: November 11, 1999Date of Patent: June 28, 2005Assignee: Pharmacia ABInventors: Torkel Gren, Anders Ringberg, Martin Wikberg, Randy J. Wald
-
Patent number: 6905708Abstract: A once a day bupropion hydrochloride formulation is disclosedType: GrantFiled: May 9, 2003Date of Patent: June 14, 2005Assignee: ANDRX Pharmaceuticals, Inc.Inventors: Boyong Li, Avinash Nangia, Chih Ming Chen, Xiu Xiu Cheng
-
Patent number: 6902746Abstract: The present invention provides oral pharmaceutical compositions for acetic acid class of non-steroidal anti-inflammatory drug (NSAID), particularly ketorolac. The pharmaceutical composition contains a core, a drug layer (which comprises the drug, a binder, and a disintegrant), a protecting layer, and an enteric coating layer. The oral pharmaceutical compositons are particularly useful for treating patients with moderate to acute pain. The present invention also provides a method for making the pharmaceutical compositions and a method for using the pharmaceutical compositions.Type: GrantFiled: July 3, 2002Date of Patent: June 7, 2005Assignee: Yung Shin Pharmaceutical Industrial Co., Ltd.Inventors: Fang-Yu Lee, Shan-Chiung Chen, Ping-Kuen Chen, Han-Chiang Kuo
-
Patent number: 6890561Abstract: There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated isoflavone-enriched fraction or mixture of such fractions, comprising at least one granulated isoflavone-enriched fraction and at least one carrier, diluent or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 75 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, at pH 6.8, and a temperature of 37° C. A process for the preparation of such a formulation is also provided.Type: GrantFiled: August 15, 2000Date of Patent: May 10, 2005Assignee: Bio Dar Ltd.Inventors: Yoav Blatt, Oded Arad, Eugene Kimelman, David Cohen, Rika Pinto, Avner Rotman
-
Patent number: 6890550Abstract: Method of preventing parturient hypocalcemia and milk fever (parturient paresis) in lactating animals comprising administering to the animal during the dry period a compound which reduces absorption of calcium from the drinking water and/or from the ration of said animal. The method is based on the powerful, natural calcium regulating mechanisms and is applicable under commercial farming conditions.Type: GrantFiled: March 17, 2000Date of Patent: May 10, 2005Assignee: RJ InnovationInventor: Rolf Jess Jorgensen
-
Patent number: 6878387Abstract: The invention relates to a pharmaceutical preparation consisting of: (a) a core containing an active substance, optionally an excipient and common pharmaceutical additives in addition to the salt of an inorganic acid whose proportion in the weight of the core ranges from 2.Type: GrantFiled: September 28, 1999Date of Patent: April 12, 2005Assignee: Roehm GmbH & Co KGInventors: Hans-Ulrich Petereit, Thomas Beckert, Eva Lynenskjold
-
Patent number: 6869615Abstract: An oral solid dosage form includes a therapeutically effective amount of an NSAID and a proton pump inhibitor in an amount effective to inhibit or prevent gastrointestinal side effects normally associated with the NSAID. Also disclosed is a method of treating a human patient in need of antiinflammatory, analgesic and/or antipyretic therapy, comprising orally administering to the patient an oral pharmaceutical dosage form which includes a therapeutically effective amount of an NSAID and an amount of a proton pump inhibitor effective to substantially inhibit gastrointestinal side effects of the NSAID. The invention is further related to a method of prophylactically treating a human patient who is on a therapy known to have significant gastrointestinal side effects or is about to begin such a therapy, via concurrent administration of an NSAID and a proton pump inhibitor in a combination (single) oral dosage form.Type: GrantFiled: October 28, 2002Date of Patent: March 22, 2005Assignee: Andrx Labs LLCInventors: Chih-Ming Chen, Unchalee Kositprapa
-
Patent number: 6858725Abstract: Granulation of microcrystalline cellulose with a granulating fluid consisting of water and a water-miscible, volatile, polar organic solvent yields porous granules which are comprised of particles that are larger than the ungranulated microcrystalline cellulose. This granulated microcrystalline cellulose is capable of cushioning controlled release particles and barrier coated particles from the compression forces used in tableting, thereby maintaining the physical integrity of the components of the tablet.Type: GrantFiled: November 9, 2000Date of Patent: February 22, 2005Assignee: R.P. Scherer Technologies, Inc.Inventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Christopher A. Sweriduk
-
Patent number: 6849271Abstract: The present invention relates to microspheres, processes for the manufacture of said microspheres, pharmaceutical compositions comprising said microspheres, and sustained release methods of administering an effective pharmaceutical amount of a bioactive compound to a subject. The microspheres of the present invention comprise a water insoluble organic matrix comprising an interior region, throughout which are homogeneously dispersed a plurality of microcapsules consisting essentially of a core of bioactive compound coated with material containing charged organic groups and a surface region substantially free of said bioactive compound.Type: GrantFiled: October 18, 2002Date of Patent: February 1, 2005Assignee: Verion, Inc.Inventors: Farid Vaghefi, Martin F. Savitzky
-
Patent number: 6849269Abstract: This invention relates to proliposomal drug-delivery systems for medicaments. In particular, it relates to enteric-coated proliposomal formulations for poorly water soluble drugs and methods for making the same. The drug delivery system comprises a pharmaceutical agent, a phospholipid and a coating material. The present invention provides enhanced stability and bioavailability for pharmaceutical formulations.Type: GrantFiled: April 24, 2002Date of Patent: February 1, 2005Assignee: Western University of Health SciencesInventor: Guru V. Betageri
-
Patent number: 6841169Abstract: The present invention relates to an auxiliary substance for an active substance, such as a pharmacon. The auxiliary substance has a stabilizing action. The auxiliary substance further has a positive influence on the bioavailability of the active substance with which the auxiliary substance can be incorporated into a pharmaceutical preparation. The auxiliary substance is based on a fructan having a number-average degree of polymerization of at least 6 and is used in the form of a sugar glass.Type: GrantFiled: December 7, 2001Date of Patent: January 11, 2005Assignee: Rijksuniversiteit GroningenInventors: Wouter Leonardus Joseph Hinrichs, Henderik Willem Frijlink
-
Patent number: 6835397Abstract: The present invention is an encapsulated yeast composite comprising a core comprising yeast and a coating containing an emulsifiable lipid. The yeast includes Saccharomyces cerevisiae. The invention also relates to other encapsulated bioactive substance composites. The nature of the coating provides controlled release of the bioactive substance from the encapsulate. The encapsulated composites are useful in the production of food compositions, food products, and animal feed products.Type: GrantFiled: January 14, 2003Date of Patent: December 28, 2004Assignee: Balchem CorporationInventors: Phillip K. Lee, Paul H. Richardson
-
Patent number: 6827930Abstract: A sport fishing system having: a rod and reel, including fishing line; at least one fishing lure or natural bait; and a controlled released fish attractant for applying to the fishing lure or natural bait. The system may further include an applicator for applying the controlled released fish attractant to the fishing lure or natural bait. In the preferred embodiment, the controlled release fish attractant includes: an attractant and a substantially hydrophobic, film forming release agent.Type: GrantFiled: September 6, 2002Date of Patent: December 7, 2004Assignee: Carolina Lunker Sauce, L.L.C.Inventors: Stephen Russell Cobb, Michael D. Jacobson, Joseph A. Lupia
-
Patent number: 6824790Abstract: This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, antioxidant or anti-inflammatory compounds to the gastrointestinal tract after oral administration.Type: GrantFiled: January 9, 2003Date of Patent: November 30, 2004Assignee: EnzRel Inc.Inventor: Milton Yatvin
-
Patent number: RE39030Abstract: A superior enteric formulation of the antidepressant drug, fluoxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.Type: GrantFiled: January 28, 2002Date of Patent: March 21, 2006Assignee: Eli Lilly and CompanyInventors: Neil Robert Anderson, Roger Garrick Harrison, Daniel Frederick Lynch, Peter Lloyd Oren
-
Patent number: RE39239Abstract: The present invention provides methods of treating early morning pathologies using a time-specific controlled release dosage formulation which is administered prior to sleep, and which permits or achieves delivery of a pharmaceutically active agent effective for the treatment of the specific early morning pathology to be treated, at about the time of awakening. The time-specific controlled release dosage formulation comprises (1) a core including the pharmaceutically active agent(s) effective for the treatment of the early morning pathology, and (2) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer, to effect delivery of the pharmaceutically active agent at about the time of awakening.Type: GrantFiled: September 17, 2002Date of Patent: August 15, 2006Assignee: Polichem SAInventors: Cesare Busetti, Tiziano Crimella